MedTrace Logo

Hippo Signaling Pathway Proteins in Gingival Crevicular Fluid of Individuals With Periodontal Disease

NCT07759466 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-08-13

No results posted yet for this study

Summary

Periodontal disease is a chronic inflammatory condition of the tooth-supporting tissues in which the host inflammatory response drives the destruction of alveolar bone and periodontal attachment. The Hippo signaling pathway is a conserved regulatory network that controls cell proliferation, apoptosis, and bone homeostasis, but its role in human periodontal disease remains unknown. This observational, case-control study compared the levels of Hippo signaling pathway proteins (YAP, TAZ, MST1, TEAD, LATS1, MAP4K4), the anti-apoptotic protein BCL-2, and the bone metabolism marker alkaline phosphatase (ALP) in gingival crevicular fluid across 75 systemically healthy participants grouped as periodontally healthy, gingivitis, or stage 3 grade B periodontitis. The aim was to determine whether these proteins are differentially expressed across periodontal health and disease states and whether they correlate with markers of apoptosis and bone metabolism.

Conditions

  • Periodontal Disease
  • Gingivitis and Periodontal Diseases
  • Biomarker Discovery and Validation
  • Pathways

Interventions

DIAGNOSTIC_TEST

ELISA Biomarker Analysis

Gingival crevicular fluid samples were collected from each participant using standardized paper strips placed into the periodontal pocket for a fixed interval, and fluid volume was measured electronically. Samples were pooled per participant and stored until analysis. The levels of Hippo signaling pathway proteins (YAP, TAZ, MST1, TEAD, LATS1, MAP4K4), the anti-apoptotic protein BCL-2, and the bone metabolism marker alkaline phosphatase were quantified by enzyme-linked immunosorbent assay according to the manufacturers' instructions. Standard curves were generated individually for each biomarker, and results were expressed both as total amounts and as concentrations to account for differences in fluid volume between groups.

Sponsors & Collaborators

Principal Investigators

  • Cüneyt A Aral, Chair, Professor, DDS, PhD · Inonu University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-03-01
Completion
2025-04-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07759466 on ClinicalTrials.gov